Martine A. Rothblatt, chief executive of United Therapeutics Corp (UTHR), sold $10.86 million of company stock in the seven day window ending October 22nd, 2026. The activity arrived not as a single block but as 35 separate Form 4 sale filings. All of it was reported by one person.
United Therapeutics is a pharmaceutical preparations company with a market capitalisation of $25,356,978,176. The last price in our table is $591.20. Only open market sales are counted here: shares withheld to cover tax and disposals back to the issuer are excluded, so the figure reflects stock sold into the market rather than paperwork around vesting.
The count of distinct sellers in the window is one. That matters for how the number should be read. A $10.86 million total spread across a dozen vice presidents is a different picture from the same total coming from a single desk, and here it is the latter.
The largest seller in the window is Rothblatt, whose role is listed as CEO. She is also the only seller in the window, which makes largest and sole the same entry. Our table carries one price for this security, the last price of $591.20, so no move across the seven days is being asserted here. Readers who want the intraday path over that stretch should pull it from a price source rather than from this record.
Thirty five filings in seven days is a pattern worth noting on its own terms. High filing counts in a short window are common when sales are executed in tranches across several sessions, which is typical of programme selling and also typical of someone working a large position down in pieces. The filings record the trades. They do not record the reasoning.
A sale is not advice and it is not a prediction. A sale may be a scheduled 10b5-1 plan entered months earlier, which means the decision to sell could predate the week in which the shares actually changed hands. Executives sell for reasons that have nothing to do with the company: tax bills, diversification, property, divorce, charitable giving, estate planning. Nothing in a Form 4 states a motive, and this article does not supply one. What follows from the document is narrow: shares were sold, on these dates, in these amounts, by this person.
It is also worth holding the figure against the size of the issuer. Against a market capitalisation of $25,356,978,176, a $10.86 million sale is a small slice of the equity, though it is a meaningful sum for an individual. Both of those things are true at once and neither one settles anything.
Sources: SEC Form 4 filings via EDGAR, reviewed by InsiderBuying.com, covering the seven day window ending October 22nd, 2026.
Track every Form 4 filed at UNITED THERAPEUTICS Corp (UTHR) → insiderbuying.com/companies/UTHR